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Background: Traditional survival estimates after resection for pancreatic cancer are based on clinico-
pathological variables at the time of diagnosis. Estimates have not reflected time survived after resection,
as investigated for other malignancies. The aim of the present study was to understand how survival
estimates change after pancreatic resection for cancer based on time already survived (conditional
survival).
Methods: Pancreatectomies performed for pancreatic ductal adenocarcinoma (PDAC) between 2001
and 2010 were reviewed. Clinicopathological variables were evaluated to identify predictors of survival.
Expected survival according to a validated nomogram for pancreatic cancer as well as conditional survival
estimates and actual survival were calculated.
Results: In all, 186 patients underwent pancreatic resection for PDAC [154 (82.8%) Whipple, 26 (14.0%)
distal and 6 (3.2%) total]. Median (range) survival was 22 (3.4–107.3) months. Predictors of overall survival
were: absence of nodal disease [odds ratio (OR) 8.8], age <67 years (OR 8.4) and lower stage (OR 4.3).
Expected survival according to the nomogram was 70% (1 year), 39.5% (2 years) and 24% (3 years). As
time passed, and overall and expected survival decreased, conditional survival increased.
Discussion: The available prognostic system for PDAC underestimated survival compared with actual
survival in the present study. Conditional survival estimates, based on accrued lifespan, were better than
either predicted or actual survival, suggesting that survival is a dynamic, rather than static, concept.
Conditional survival may, therefore, be a useful tool to allow patients and clinicians to project subsequent
survival based on time accrued since resection.
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Introduction
After the diagnosis and operative management of pancreatic
adenocarcinoma (PDAC), themost common question patients ask
is what their anticipated survival may be. Traditional survival
estimates after resection for PDACare based on clinicopathological
variables established at the time of diagnosis and surgery, and are
often grim1. Thus far, estimates have not reflected time survived
after resection and so, in follow-up, survival estimates remain
unchanged, based on pre-operative and operative data alone.
However, conditional survival has been investigated in other
malignancies including colorectal cancer liver metastases,2 where
it has been found to provide more accurate prognostic informa-
tion, particularly over time and for patients thought to be high
risk but who survived longer than expected. Conditional survival
(CS) is defined as the probability of surviving an additional
number of years/months, based on a specific length of time
already survived. Conditional survival estimates account for time
already survived when determining ongoing survival estimates,
i.e. from that point onwards. The aim of the present study was to
understand whether survival estimates after pancreatectomy for
PDAC change with time survived post-operatively, in order to be
able to better explain post-operative survival to patients.
This paper was presented at the American Hepato-Pancreato-Biliary
Association 11th Annual Meeting, Miami, FL, USA.
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Methods
Under Institutional Review Board (IRB) approval, data on all
pancreatectomies performed with curative intent for pancreatic
ductal adenocarcinoma (PDAC) by three pancreatic surgical spe-
cialists between 2001 and 2010 were reviewed from a prospectively
maintained database. Resection was classified as a pancreati-
coduodenectomy, distal or total pancreatectomy. All major resec-
tions were incorporated in accordance with inclusion criteria for
theMemorial Sloan Kettering Cancer Center (MSKCC) Pancreatic
CancerNomogram(Brennan),where requireddata points include:
location of the lesion and splenectomy, indicative of type of opera-
tion performed. Peri-operative care followed the standardized
post-operativeCarepath for Pancreatic Resection.3,4 Date of the last
follow-up, adjuvant therapy, survival status and clinicopathologi-
cal variables were tabulated. During the timeframe of the study,
annual volume increased. Additionally, over this time, cyberknife
radiotherapywas incorporated into the adjuvant therapy tools, but
neoadjuvant therapy was not routinely employed.
Statistical analysis was performed using SAS 9.2 (SAS Inc., Cary,
NC, USA). Clinicopathological variables were evaluated to iden-
tify predictors of survival in univariate and multivariate regres-
sion analysis. As is standard, statistical significance was established
as P = 0.05.Expected survival was calculated and defined according
to a validated nomogram for pancreatic cancer.5 CS was defined as
the probability of surviving an additional number of years/
months, based on time already survived. CS was calculated
according to the formula:2 CSy = S(x+y)/Sx, where x = years survived
and y = additional years. Previous papers have referred to the
‘5-year CS5’, as the probability of surviving a second 5-year period
(10 years total) based on initial 5-year survival.2,6 This paper uses
the same formula to calculate shorter and variable CS, given the
more aggressive natural history of PDAC and its shorter overall
survival compared with other previously investigated cancers.
Results are presented and discussed as the probability of surviving
a total period of time, i.e. 3 years, based on initial survival at 1 and
2 years. Conditional survival probability is presented with actual
survival and nomogram-based survival estimates serving as refer-
ence points. Actual survival was calculated individually and
directly, based on months survived compared with eligibility for
analysis at that point. No estimation of additional survival was
undertaken for censoring; thus, the actual, rather than actuarial,
survival is incorporated, according to previously reported defini-
tion and methodology.7
Results
In all, 188 patients underwent pancreatic resection for PDAC (156
Whipple, 26 distal and 6 total) between 2001 and 2010. Two
patients who had undergone a Whipple procedure were excluded
because their pathology could not be utilized for staging per the
nomogram: in one patient, the primary tumour origin could not
be confirmed as PDAC, and in the other patient, no residual
tumour was identified after neoadjuvant treatment. Between 2001
and 2010, 154 (82.8%), 26 (14.0%) and 6 (3.2%) patients under-
went a Whipple, distal or a total pancreatectomy, respectively.
Overall median survival was 22 months (3.4–107.3 m) and
5-year survival was 20%. Figure 1 demonstrates the percentage of
patients surviving at each time point, accounting for eligibility, i.e.
length of follow-up. The slope of this curve lessens as time passes,
again reflecting the concept of conditional survival, in which the
likelihood of further survival increases the further the patient is
from the time of diagnosis. In univariate analysis, negative nodes
(P < 0.001) and lower stage (P < 0.001) predicted 5-year survival.
In multivariate regression analysis, predictors of 5-year survival
included: age < 67 years [odds ratio (OR) 8.4, 1.0–69], lower stage
(OR 4.3, 1.1–17.1) and negative nodes (OR 8.8, 1.3–60.3). Patient
characteristics in terms of the required input for the MSKCC
nomogram are listed in Table 1, in comparison to the MSKCC
patient characteristics.8 According to the nomogram, expected
survival was 70% at 1 year, 39.5% at 2 years and 24% at 3 years.
Conditional survival results are detailed in Table 2. The reader
will note that these conditional survival calculations begin at some
time (6 months, in the present study) after the initial entry into
the system. This reflects both the purpose of conditional survival
calculations, for modulation of survival estimates in longer-term
follow-up, and also the equation itself, by which calculation results
would equal actual survival at time zero. As a reference point,
expected survival based on the nomogram and actual survival are
included. At each total survival time, the conditional survival esti-
mates increased per length of time already survived, even as
overall and predicted survival decreased. For example, at 5 years,
actual survival is 20%. Given the patient survived 6 months, the
probability of surviving an additional 4.5 years (to a total of 5) is
0.255 (or 25.5%). The probability increases with additional time
survived from the initial time, such that of patients surviving to
the 2-year mark, 47.3% would survive an additional 3 years to a
Figure 1 Patients surviving compared to patients eligible for survival
analysis at that time point, based on date of procedure and length of
follow up
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total of 5 years, and of those surviving to 4 years, 81% would
survive the additional 1 year, to a total of 5 years.
Conditional survival was then stratified by age groups, nodal
status and T-stage (Fig. 2). Overall, younger age was predictive of
5-year survival in the multivariate regression analysis. When
stratified by age and by year(s) already survived, the younger
patients initially had a higher conditional survival, but those older
patients who did survive to the 3-year mark, were more likely than
the younger patients to survive to 5 years. Stratifying the patients
by lower (T1, T2) and higher (T3, T4) T-stage demonstrates the
better conditional survival for the lower stage patients. However,
all T3/4 patients who survived to 4 years and were 5 or more years
out from their surgical date did survive to 5 years (n = 6). Lymph
node negative patients had better conditional survival than lymph
node positive patients at each time point. In all, 123 patients were
known to undergo chemotherapy (65.4% of all patients) and 92
patients underwent radiation therapy (48.9%), usually in combi-
nation with chemotherapy. Adjuvant therapy data were unable to
be determined in 45 (24.2%) patients who stated a preference for
treatment closer to home but did not return for tertiary institu-
tional follow-up. These patients were thus lost to follow-up other
than for survival data, given the constraints of our IRB approval
for the database.
Discussion
Pancreatic cancer is commonly understood to be an aggressive
disease. Patients who receive this diagnosis are largely ineligible
for resection.9 Even when patients are found to have resectable
disease, survival is fairly dismal, certainly in comparison to other
cancers, such as cancer of the breast, prostate, or colon.1 The study
of survival, therefore, takes on a different, and often more limited,
scope.
Brennan et al. have published a prognostic nomogram5 for up
to 3 years, to assist in pre-operative and immediate post-operative
survival estimations. The nomogram provides more specific esti-
mates than survival based on TNM staging alone, as it accounts
for patient and tumour features known at the time of surgery.10 It
has been validated by other groups.8,10 Using this nomogram as it
applies to our practice of pancreatectomy for PDAC, expected 1, 2,
and 3-year survival was 70, 39.5, and 24%, respectively. Actual
5-year survival was 20%. As discussed by Ferrone et al., the post-
resection nomogram is an important tool for short-term stratifi-
cation, potentially for defining entry criteria for adjuvant therapy
trials.8 They also comment that the nomogram can provide a
more realistic survival estimate for patients, based on the unique
features of the patient and the tumour.
This point is worth considering further as time goes on, yet
survival estimates are not usually adjusted for time passed.
Therein lies the relevance of the conditional survival concept: to
be able to adjust our survival estimates in an ongoing manner as
time passes, in order to inform patient discussions and impact
quality of life for the pancreatic cancer patient. The present
study demonstrates that conditional survival, in which time sur-
vived is accounted for in subsequent survival estimates, exceeds
expected and actual survival. This concept has been investigated
previously on a database-wide level, where improvements in sur-
vival estimates accounting for time already survived was greatest
for the most lethal cancers, including lung and pancreas.6 In fact,
5-year survival for pancreas cancer patients who had survived
the first 5 years, was greater than 90%.6 Practice-level data
provide a different perspective than Surveillance Epidemiology
and End Results (SEER) data, as it has the capacity to account
for standardization within a singular practice. An additional goal
was to investigate conditional survival calculations using variable
time points, in contrast to the previous papers2,6 in which the
concept has been framed as a 5-year re-evaluation of survival.
Given the often grim prognosis and fairly short typical survival
even for resected patients, the authors felt it would be useful to
look at conditional survival at shorter time intervals. Condi-
tional survival estimates here were further stratified according to
those factors found to be significant in regression analysis. Simi-
larly conditional survival continued to improve for each group
in the stratified analyses but with some variation. Overall,
Table 1 Patient characteristics (required for nomogram)
Current
patients
MSKCC
patients
n (186) % %
Age (mean) 62.4 N/A 65
Female gender 97 51.6 50%
Portal vein resection/
reconstruction
6 3.2 14%
Back pain 30 16.1 14%
Weight loss 87 46.8 54%
Splenectomy 30 16.1 10%
Margin positive 69 37.1 21%
Posterior margin positive 17 9.1 14%
HOP mass 160 86 89%
T-stage
T1 14 7.5 4%
T2 39 21 12%
T3 130 69.9 80%
T4 2 1.1 1%
Unknown 1 0.5 3%
Lymph nodes positive 117 62.2
Differentiation
Well 31 16.8 14%
Moderate 101 54.9 54%
Poor 52 28.3 28%
HOP, head of the pancreas; MSKCC, Memorial Sloan Kettering Cancer
Center.
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younger age predicted 5-year survival. Younger patients had
better shorter-term conditional survival but those older patients
who survived to 3 and 4 years, were more likely than the younger
patients to survive to 5 years. Perhaps this finding reflects some
self-selection, in terms of those patients who may have been
strong enough to complete adjuvant therapy. In the present
study, lymph node negativity was the strongest predictor of
long-term survival and afforded better conditional survival at
each time point.
For this concept to be best applied in a fairly lethal disease, a
large patient cohort is required,2 given the expected death rates,
and a long follow-up allows longer projection in the future. The
present study incorporates the pancreatectomies for cancer in a
single practice with standard peri-operative care,3 and common-
alities of medical oncology practice, and we feel, represents a
starting point for ongoing analysis of this concept. Nonetheless,
the lack of complete information about disease-free survival given
local versus institutional follow-up, and the small sample size here
still clearly limit the interpretation of results, and longer follow-up
will be required to project survival out to 10 years and longer.
The reason for the difference in survival estimates may be, at
least in part, as a result of features of the tumour biology that are
not yet fully understood. For example, standard staging for pan-
creatic cancer falls under the TNM staging system. However, a
recent paper demonstrates the importance of tumour grade on
prognostication and purports that it should be included in the
staging of pancreatic cancer.11 Even in the absence of further
knowledge about these individual tumour biology features, the
use of conditional survival allows for the adjustment of survival
estimates as time goes on.
Conditional survival estimates are not intended to have
pre-operative utility. Certainly the nomogram and TNM staging
currently provide some starting survival estimates, but they
matter less as time goes by. Conditional survival allows the phy-
sician to adjust these survival estimates as the patient
continues to survive. This concept has been discussed with
respect to less lethal malignancies, including in the recent paper
on colorectal liver metastases survival by Nathan et al.,2 as par-
ticularly useful because patients are surviving longer after liver
resection.
However, the application of the same concept to more lethal
cancers such as pancreatic cancer still provides the patient with
additional confidence in future survival if he/she has already sur-
vived up to or beyond what was initially forecasted. Previous work
on the transition from active cancer patient to survivor with the
conclusion of adjuvant treatment identifies an association
between uncertainty and both functional and physical impair-
ment.12 Literature primarily from the nursing perspective on other
cancers such as breast and colon demonstrates the negative impact
of uncertainty of recurrent disease and survival on the patient’s
Table 2 Expected, actual, and conditional survival for resected pancreatic ductal adenocarcinoma (PDAC) (%)
Total survival Expected survival Actual
survival
Survival conditional on initial:
6 months 12 months 18 months 24 months 36 months 48 months
6 months – 93.6
12 months 70 78.5 83.6
18 months – 60.9 65.1 77.6
2 years 39.5 42.3 45.2 53.9 69.4
3 years 24 26.2 28 33.4 43.1 62.1
4 years – 24.7 26.4 31.4 40.5 58.4 94.1
5 years – 20 21.4 25.5 32.8 47.3 76.2 81
Figure 2 Conditional survival stratified by age, T-stage, and lymph node status. Conditional survival was better for the younger patients
overall, lower T-stage, and negative lymph node status
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quality of life after cancer treatment,13–15 which suggests that
relieving some of that uncertainty may potentially improve the
patient’s quality of life.16
Conclusions
The available prognostic scoring system for PDAC underesti-
mated survival compared with actual survival in the present
study. Conditional survival estimates, based on accrued lifespan,
were better than either predicted or actual survival at multiple
time points. This finding suggests that survival is a dynamic,
rather than static, concept. Patient quality of life is often
impacted by uncertainty regarding survival. While that uncer-
tainty cannot currently be eliminated, conditional survival esti-
mates may be able to predict survival more appropriately based
on time survived as a marker for currently undefined tumour
biological factors. Conditional survival may therefore be a useful
tool in the post-operative setting to allow patients and clinicians
to project subsequent survival based on time accrued since
resection. Ongoing study of this concept is required to make
these estimations more robust.
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